Table 3 Associations between inflammation biomarkers and risk of lung cancer.

From: Circulating gamma-glutamyl transpeptidase, systemic inflammation biomarkers and risk of lung cancer in the UK biobank prospective cohort study

Inflammation biomarkers

HR (95% CI) for per

HR (95% CI) according to biomarkers concentration in median

HR (95% CI) according to inflammation biomarkers concentration in quartiles

increase

Increase

HR (95% CI)

Q1

Q2

Q3

Q4

P trend

Lymphocyte count

1*10^9/L

1.065 [1.050, 1.082]

1.200 [1.119, 1.287]

1(reference)

1.088 [0.979, 1.209]

1.148 [1.037, 1.270]

1.364 [1.236, 1.506]

< 0.001

Neutrophill count

1*10^9/L

1.169 [1.148, 1.190]

1.524 [1.416, 1.639]

1(reference)

1.081 [0.961, 1.217]

1.299 [1.162, 1.453]

1.854 [1.670, 2.058]

< 0.001

Platelet count

1*10^9/L

1.002 [1.001, 1.002]

1.258 [1.176, 1.346]

1(reference)

1.012 [0.918, 1.116]

1.164 [1.058, 1.281]

1.373 [1.250, 1.507]

< 0.001

NLR

1 unit

1.039 [1.030, 1.047]

1.203 [1.125, 1.285]

1(reference)

1.004 [0.909, 1.109]

1.127 [1.022, 1.242]

1.285 [1.168, 1.413]

< 0.001

PLR

100 unit

1.016 [0.991, 1.041]

0.952 [0.889, 1.019]

1(reference)

0.939 [0.860, 1.025]

0.879 [0.801, 0.965]

0.976 [0.889, 1.071]

0.046

SII

100 *10^9/L

1.017 [1.014, 1.020]

1.259 [1.178, 1.345]

1(reference)

1.067 [0.965, 1.180]

1.144 [1.037, 1.262]

1.451 [1.323, 1.592]

< 0.001

White blood cell count

1*10^9/L

1.077 [1.070, 1.084]

1.589 [1.475, 1.713]

1(reference)

1.136 [1.005, 1.284]

1.437 [1.282, 1.611]

1.953 [1.752, 2.177]

< 0.001

C-reactive protein

10 mg/L

1.331 [1.272, 1.393]

1.623 [1.507, 1.748]

1(reference)

1.243 [1.103, 1.400]

1.562 [1.394, 1.750]

2.131 [1.909, 2.379]

< 0.001

  1. NLR neutrophil-to-lymphocyte ratio, PLR, platelet-to-lymphocyte ratio; SII systemic immune-inflammation index. Analyses were adjusted for adjusted for age at recruitment, sex, education level, Townsend deprivation index, body mass index, smoking status, family history of lung cancer, alcohol intake frequency, liver disease status at the baseline.